![]() |
![]() |
![]() |
![]() |
0-Mo | Registry of Clotting Factor Concentrates | Mark Brooker | ![]() |
![]() |
|||
1-We | Prevalence of Cardiovascular Disease or its Equivalents in Patients withInherited Coagulopathies | M. CEM AR | ![]() |
![]() |
|||
2-Mo | Patterns of bleeding, comorbidities and clinical courses in Acquired HemophiliaA(AHA) and in Acquired von Willebrand Disease (AVWD): experience from a singleHemophilia Center of Pavia | Gabriella Gamba | ![]() |
![]() |
|||
2-We | Carotid endarterectomy in two persons with Haemophilia | Louise Bowles | ![]() |
![]() |
|||
3-We | DESCRIBING OCCURRENCE OF CORONARY EVENTS AND TREATMENT IN HAEMOPHILIACS (DOCETHREGISTRY): REPORT OF 27 PATIENTS. | Antonio Coppola | ![]() |
![]() |
|||
3-Mo | Acquired hemophilia - clinical course and treatment outcomes in 25 patients | Denisa Jankovicova | ![]() |
![]() |
|||
4-LB | Trends in invasive orthopedic interventions for individuals with a bleeding disorder enrolled in the Universal Data Collection | Patricia Tobase | ![]() |
![]() |
|||
4-Mo | ACQUIRED HAEMOPHILIA AT CHRIS HANI BARAGWANATH ACADEMIC HOSPITAL | MOOSA PATEL | ![]() |
![]() |
|||
4-Tu | INTEGRATING AGEING WITH A BLEEDING DISORDER INTO CANADIAN HEMOPHILIA SOCIETY(CHS) STRATEGIES | Clare Cecchini | ![]() |
![]() |
|||
5-We | Cataract surgery in haemophilia | Dietje Fransen van de Putte | ![]() |
![]() |
|||
6-Tu | THE IMPORTANCE OF MULTIDISCIPLINARY APPROACH TO PATIENTS WITH HEMOPHILIA | Glbahar Keskin | ![]() |
![]() |
|||
6-We | Ageing and quality of life in persons with hemophilia | Marko Marinic | ![]() |
![]() |
|||
7-We | Nursing the aging haemophiliac:Cardiovascular challenges | Cathy Mumby | ![]() |
![]() |
|||
7-Mo | HIGH DOSE OF FVIII CONCENTRATE AS FIRST LINE THERAPY IN FOUR PATIENTS AFFECTEDBY ACQUIRED HAEMOPHILIA A AND CARDIOVASCULAR DISEASE | Ezio Zanon | ![]() |
![]() |
|||
7-Tu | A Recruitment Plan for Volunteers | Brian OMahony | ![]() |
![]() |
|||
8-Tu | Canadian Hemophilia Society Involvement in Canadas Blood System | David Page | ![]() |
![]() |
|||
8-We | Newly emerging problems among aging patients with hemophilia in Japan | Azusa Nagao | ![]() |
![]() |
|||
9-We | The Elderly Hemophilia Population - A Nordic Patient Organisation Prospective | Suzanne Ceder | ![]() |
![]() |
|||
10-We | Patterns of gastrointestinal hemorrhage in hemophilia. | ajmi naourez | ![]() |
![]() |
|||
11-We | The medical and economic burden of mild hemophilia in comparison to the severetype: long term data from a german single center | Christoph Bidlingmaier | ![]() |
![]() |
|||
12-Tu | Prospective and challenges of pediatric hematology at KFSH&RC, Riyadh, Saudi Arabia | MAHASEN SALEH | ![]() |
![]() |
|||
12-We | Technical issues in implementing prophylaxis in children with hemophilia: aninternational survey | Christoph Bidlingmaier | ![]() |
![]() |
|||
13-Tu | Impact of training the trainers in haemophilia care in Pakistan | Tahira Zafar | ![]() |
![]() |
|||
14-Mo | The European Haemophilia Network (EUHANET) project | Michael Makris | ![]() |
![]() |
|||
14-We | CAUSES OF DEATH IN PATIENTS WITH HEMOPHILIA ATTENDED AT THE NATIONAL HEMOPHILIACENTER OF VENEZUELA (1989- 2011) | Apsara Boadas de Sanchez | ![]() |
![]() |
|||
15-Tu | EXPERIENCE IN THE TREATMENT OF CUBAN PATIENTS WITH SEVERE BLEEDING USINGRECOMBINANT FVIIA | Dunia de la Caridad Castillo González | ![]() |
![]() |
|||
15-We | CARDIAC SURGERY IN HAEMOPHILIACS : REPORT OF 14 CONSECUTIVE CASES | Marie-Elisabeth Briquel | ![]() |
![]() |
|||
16-Mo | Patient Organisation involvement in management of Hepatitis C | Brian OMahony | ![]() |
![]() |
|||
17-Mo | Muoviamoci (Italian Musculoskeletal Global Project) | Gianluigi Pasta | ![]() |
![]() |
|||
18-Mo | Fostering collaboration in hemophilia care | Jayson Stoffman | ![]() |
![]() |
|||
19-We | Evaluation of the utilization of factor concentrate and frequency of bleedsamong the patients with severe and moderate Factor VIII and Factor IX deficiency | Roya Dolatkhah | ![]() |
![]() |
|||
19-Mo | Mild Haemophilia may hide severe haemophilia. | Philippe BEURRIER | ![]() |
![]() |
|||
20-Tu | Variable Activation Kinetics of Different Recombinant Full Length and B-DomainDeleted Factor VIII Concentrates | Saskia Pahl | ![]() |
![]() |
|||
20-Mo | Pregnancy outcome in haemophilia A carriers over a 5 year period in a UKHaemophilia Comprehensive care centre (CCC) | Deepa Ranjani Jayakody Arachchillage | ![]() |
![]() |
|||
21-We | Usefulness of Multidetector Computed Tomography Angiography (MDCTA) inhemophilic patients previous to embolization of the middle geniculate artery(MGA) | Matilde Hernandez-Trejo | ![]() |
![]() |
|||
21-Tu | One Year Clinical Experience with Mini-Pool Solvent/Detergent-filtered (SD-F)Plasma | El Ekiaby Magdy | ![]() |
![]() |
|||
23-We | Comprehensive Spectrum of inherited bleeding disorders from South West Iran | Bijan Keikhaei | ![]() |
![]() |
|||
24-We | Role of angiogram and embolisation in patients with haemophilia | Shyamkumar Keshava | ![]() |
![]() |
|||
25-Mo | Hemophilia in Taiwan: a Population-Based Study on Epidemiology, Age atDiagnosis, Mortality, and 13-year Trend by National Health Insurance ResearchDatabase 1997-2009 | Chia-Yau Chang | ![]() |
![]() |
|||
25-Tu | CTP - A CLINICALLY VALIDATED TECHNOLOGY FOR ELONGATING THE HALF LIFE OF COAGULATION FACTORS, ENABLING A PROLONGED HAEMOSTATIC ACTIVITY IN HEMOPHILIC ANIMAL MODEL | Gili Hart | ![]() |
![]() |
|||
26-We | Obesity and Haemophilia - Review of an MDT weight management service. | Paul McLaughlin | ![]() |
![]() |
|||
29-Mo | Updating the National Registry of People with clotting deficiencies in Mexico | Carlos Gaitán-Fitch | ![]() |
![]() |
|||
29-We | Correcting Dilutional Coagulopathy in Haemophilia | Renu Riat | ![]() |
![]() |
|||
30-We | Prevalence of sporadic and familial severe haemophilia: is anything changed? | riccardi federica | ![]() |
![]() |
|||
30-Tu | Analysis of the Composition of a Factor VIII Concentrate, Optivate | Sarah Kingsland | ![]() |
![]() |
|||
31-We | CLINICAL AND EPIDEMIOLOGICAL PROFILE OF CONGENITAL COAGULOPATHY PATIENTSATTENDING AT GENERAL EMERGENCY DEPARTMENT | M. Angelica Rivera | ![]() |
![]() |
|||
33-Mo | Long-term course of the severe haemophilia A or B patients in Sweden: Results from a cohort register study | Susanna Lvdahl | ![]() |
![]() |
|||
33-Tu | In vitro reversal of the direct Xa inhibitor Rivaroxaban using High Purityfactor X concentrate (FACTOR X) | Joanne Lloyd | ![]() |
![]() |
|||
34-Tu | In vitro Characterisation of FACTOR X in Global Haemostasis Tests | Joanne Lloyd | ![]() |
![]() |
|||
34-Mo | REALITY OF THE HEMOPHILIAS IN PANAMA | MORENO BELGICA | ![]() |
![]() |
|||
35-We | Hemophilia in developing countries: clinical profile of Cameroonian patients | Tayou Tagny Claude | ![]() |
![]() |
|||
35-Mo | Australian Bleeding Disorders Registry(ABDR) - an update | Joihn Rowell | ![]() |
![]() |
|||
36-Tu | Repeated Application of a new Recombinant Factor IX in Rats and Macaques | Eva Muchitsch | ![]() |
![]() |
|||
37-Tu | Preclinical Safety of a new Recombinant Factor VIIa | Eva Muchitsch | ![]() |
![]() |
|||
38-Tu | Safety of a PEGylated variant of recombinant factor VIII after repeated application in rats and macaques | Eva Muchitsch | ![]() |
![]() |
|||
39-Tu | Absorption, Metabolism, Distribution, and Excretion of a PEGylated Variant ofRecombinant Factor FVIII Following Intravenous Administration to Rats | Eva Muchitsch | ![]() |
![]() |
|||
39-We | Intracranial bleeds in bleeding disorders: a Northern Pakistan experience | Tahira Zafar | ![]() |
![]() |
|||
40-Tu | Pharmacokinetics (PK) of recombinant and plasma-derived factor VIII (FVIII) products in pediatric patients with severe hemophilia A | Melanie Steele | ![]() |
![]() |
|||
41-We | The importance of the pediatric hemostaseologist:cohort of pediatrichemostaseology patients in a tertiary german out-patient center | Sabine Irene Heine | ![]() |
![]() |
|||
42-We | Synoviorthesis with rifampicin as a adjuvant treatment of hemophilic arthropathy | Pan Ru-Yu | ![]() |
![]() |
|||
43-Tu | Roman Numerals to Denote Clotting Factors: A Potential Source of Medical Errors | David Page | ![]() |
![]() |
|||
43-We | Nutritional study in haemophilic patients by using social networks | Gianluca Sottilotta | ![]() |
![]() |
|||
43-Mo | National plan of control of heamophilia. The Moroccan national plan | El Khorassani Mohamed | ![]() |
![]() |
|||
44-Mo | Cost assessment of implementation of ITI in Iran | PEYMAN ESHGHI | ![]() |
![]() |
|||
44-Tu | CRYOPRECIPITATE TRANSFUSION IN ON-PUMP CARDIAC SURGERY | Katerina Pavenski | ![]() |
![]() |
|||
44-We | Experience on the management of malignancy in hemophilia patients. | Paula Villaca | ![]() |
![]() |
|||
45-Mo | Evidence for mobilizing policy on hemophilia in India : I. Utility of hemophiliaregistry data from Maharashtra, 1989-2009 | Anita Kar | ![]() |
![]() |
|||
45-Tu | Characterization of the binding properties of recombinant FVIII concentrateswith von Willebrand Factor | Daniele Pillitteri | ![]() |
![]() |
|||
46-Mo | Evidence for mobilizing policy on hemophilia in India: II. An estimate of treatment gap in Maharashtra | Anita Kar | ![]() |
![]() |
|||
46-Tu | Factor XIII levels in Haemophilia; Treatment Implications | Ole Halfdan Larsen | ![]() |
![]() |
|||
47-We | Nutritional Intake and Bone Mineral Density in Boys with Severe Hemophilia. | Cecily Bos | ![]() |
![]() |
|||
47-Mo | Indirect Costs Among Persons With Hemophilia B: Hemophilia Utilization Group Study Part Vb (HUGS Vb) | Mimi Lou | ![]() |
![]() |
|||
48-We | Low Bone Mineral Density and Increased Fat Mass in Boys with Severe Hemophilia. | Cecily Bos | ![]() |
![]() |
|||
48-Tu | Efficacy of a Recombinant Factor IX in Mouse Models of Hemophilia B | Eva-Maria Muchitsch | ![]() |
![]() |
|||
48-Mo | Economic impact of an efficient inclusive national tender system for factorconcentrates | Brian OMahony | ![]() |
![]() |
|||
49-Tu | Efficacy of a New Recombinant Factor VIIa in Animal Models of Hemophilia | Eva-Maria Muchitsch | ![]() |
![]() |
|||
49-Mo | Characterising Excessive School and Work Absenteeism in Hemophilia A: Hemophilia Utilization Group Study Part Va (HUGS Va) | Jiat Ling Poon | ![]() |
![]() |
|||
50-Tu | Efficacy of a PEGylated Variant of Recombinant Factor VIII in Mouse Models ofHemophilia A | Eva-Maria Muchitsch | ![]() |
![]() |
|||
50-Mo | A NEW METHODOLOGY TO ASSESS UTILITY IN HAEMOPHILIA USING QUALITY OF LIFEMEASURES IN PARENTS AND CAREGIVERS: THE CAREGIVERS BURDEN STUDY | silvia riva | ![]() |
![]() |
|||
51-Mo | COST OF IMMUNE TOLERANCE INDUCTION IN HEMOPHILIA A PATIENTS: RESULTS FROM THE ITER STUDY | silvia riva | ![]() |
![]() |
|||
52-Mo | PHARMMACOECONOMIC EVALUATION WITH AN ACTIVATED PROTHROMBIN COMPLEX CONCENTRATE(APCC) IN PATIENTS WITH HAEMOPHILIA AND INHIBITORS (PRO-FEIBA STUDY) | silvia riva | ![]() |
![]() |
|||
52-Tu | Collaborative Study for the Establishment of Korean Standard for Blood Products(Factor IX Concentrate) | JiSuk Seo | ![]() |
![]() |
|||
52-We | Managing major surgical operations in a large haemophilia centre in NorthernIndia | Naresh Gupta | ![]() |
![]() |
|||
53-Mo | COST OF ILLNESS ANALYSIS OF HAEMOPHILIA A: RESOURCES USE AND DIRECT COSTS INITALY | Michele Schino | ![]() |
![]() |
|||
53-Tu | The stability of FVIII in cold condition | Rahajuningsih Dharma Setiabudy | ![]() |
![]() |
|||
54-Tu | A case of inhibitor to factor IX in a two years old boy with severe congenitalhaemophilia B. | skhiri rania | ![]() |
![]() |
|||
55-Mo | Budget impact of FVIII concentrates taking into account the incidence of de novoinhibitor formation in PTPs: a breakeven analysis applied to ADVATE in theItalian context. | Giuseppe Turchetti | ![]() |
![]() |
|||
56-Mo | A cost-effective provincial redistribution system to prevent wastage of clottingfactor concentrates | Sarah Crymble | ![]() |
![]() |
|||
57-Tu | 2D-DIGE As a Tool to Analyze Lot-to-Lot Consistency of Complex TherapeuticProducts Such As BAX 855, a PEGylated Recombinant FVIII | Peter L. Turecek | ![]() |
![]() |
|||
58-Tu | Influence of expression of recombinant human ADAMTS13 in cell lines fromdifferent species on its glycosylation pattern and pharmacokinetics | Peter L. Turecek | ![]() |
![]() |
|||
58-Mo | Antihemophilic factors (AH) : comparative analysis and monitoring of spending atthe University Hospital of Dijon | ELODIE PHILIPPE | ![]() |
![]() |
|||
59-Tu | Establishment of a manufacturing process for recombinant human ADAMTS13retaining high specific activity | Peter L. Turecek | ![]() |
![]() |
|||
59-We | Safety of continuous rFVIII-FS infusions via 8-hour 250cc 0.9 IV bag | Angela Lambing | ![]() |
![]() |
|||
59-Mo | Disarray to Distinction: fast track restructuring of hemophilia care in HongKong. | Wing Au | ![]() |
![]() |
|||
60-Tu | Susceptibility of von Willebrand factor from different mammalian species tocleavage by human recombinant ADAMTS13 | Peter L. Turecek | ![]() |
![]() |
|||
60-Mo | Telemedicine in Haemophilia: Virtual Consultation for the haematologist atpatients home. | JOSÉ ANTONIO AZNAR | ![]() |
![]() |
|||
61-Mo | A project to establish a clinical and social assistance infrastructure inAfghanistan | Franco backhaus | ![]() |
![]() |
|||
62-Tu | Development of a large scale production process for BAX 855, a PEGylated rFVIIIproduct | Peter L. Turecek | ![]() |
![]() |
|||
63-Tu | Functional characterization of BAX 855, a PEGylated recombinant FVIII | Peter L. Turecek | ![]() |
![]() |
|||
64-Tu | Assessment of preclinical safety for BAX 326, Baxters recombinant human factorIX | Peter Turecek | ![]() |
![]() |
|||
65-Tu | Structural characterization of BAX 855, a PEGylated recombinant FVIII | Peter L. Turecek | ![]() |
![]() |
|||
65-Mo | How to manage a heamophilia treatment centre in an emergent country. TheMoroccan experience. | El Khorassani Mohamed | ![]() |
![]() |
|||
66-Mo | A National Infrastructure for Rare Blood Disorders: An Evaluation of Staffing,Training and Services in the US Federally-supported Hemophilia Treatment Centers | Ann Forsberg | ![]() |
![]() |
|||
66-Tu | Characterization of BAX 817 a recombinant FVIIa drug candidate | Peter L. Turecek | ![]() |
![]() |
|||
67-Tu | Characterization of BAX 326 a recombinant human factor IX drug candidate | Peter L. Turecek | ![]() |
![]() |
|||
67-Mo | Governing as governance in a NMO | Daniel-Aníbal García-Diego | ![]() |
![]() |
|||
68-Mo | Unique just like you | Eduardo Garzon | ![]() |
![]() |
|||
68-Tu | Safety of BAX 855, a polyethylene glycol (PEG) conjugated full-lengthrecombinant Factor VIII product | Peter Turecek | ![]() |
![]() |
|||
70-We | Restorative dentistry and third molar surgery in patient with an inhibitor toFVIII. A case report. | Bozidar Brkovic | ![]() |
![]() |
|||
71-Tu | Contribution of chromatography to virus and TSE removal in the FactorVIII/VWFOptivate process | Peter Feldman | ![]() |
![]() |
|||
71-Mo | From nothing to comprehensive hemophilia care -an experience of Karnataka Hemophilia Society | sandeep H S | ![]() |
![]() |
|||
71-We | Caries study, oral hygiene and changes on dental surfaces associated withfructose consumption in haemophilic patients and Von Willebrand | Evelyn González de Delgado | ![]() |
![]() |
|||
72-We | A review of dental surgical operations in 64 patients from a large haemophiliacentre in Northern India | Naresh Gupta | ![]() |
![]() |
|||
72-Mo | Strategic Advocacy program to involve Government in Hemophilia care: anexperience from India | Suresha Hanagavadi | ![]() |
![]() |
|||
73-Mo | Collaborative Working: The Newcastle Initiative | Chris James | ![]() |
![]() |
|||
73-We | Dental Surgery with minimal factor support update assessment of 120 patients | Ian Hewson | ![]() |
![]() |
|||
74-We | A specialized dental care programme for people with congenital coagulopathiesoffered in the Hemophilia Unit of Vall dHebron Hospital | Rafael Parra | ![]() |
![]() |
|||
74-Mo | Developing Recommendations for the UK Government on Haemophilia services & NHSReform | Chris James | ![]() |
![]() |
|||
74-Tu | USE OF HIGH DOSES FVIII/ VON WILLEBRAND FACTOR CONCENTRATE IN A PATIENT WITHTYPE III VON WILLEBRAND DISEASE AND HIGH LEVEL INHIBITOR | M Nieves Alonso Escobar | ![]() |
![]() |
|||
75-Mo | Encouraging positive change for people with bleeding disorders through a national awards scheme | Chris James | ![]() |
![]() |
|||
75-We | Periodontal management of Malagasy hemophiliacs | Simone RAKOTO ALSON | ![]() |
![]() |
|||
76-Mo | Asha Kiran - Summer camps to empower persons with hemophilia and their families. | Annamma Joseph | ![]() |
![]() |
|||
76-We | Oral Health Status and Oral Health Related Quality of Life in IranianHemophilic Pediatric Patients | Katayoun Salem | ![]() |
![]() |
|||
77-Mo | Kite flying - A unique idea for public awareness and fund raising. Experience from a rural hemophilia centre in India. | Annamma Joseph | ![]() |
![]() |
|||
77-Tu | Adaptation in hemophilia A patients during long term prophylactic treatment | Anna Balandina | ![]() |
![]() |
|||
78-We | A minimally invasive method for the diagnosis of lesions affecting the jaws | Federico Stolbizer | ![]() |
![]() |
|||
79-We | DENTAL MANAGEMENT OF CHILDREN WITH BLEEDING DISORDERS - THE KUALA LUMPURHOSPITAL EXPERIENCE | NORAINI NUN NAHAR YUNUS | ![]() |
![]() |
|||
80-We | Statistics of Dental Attention Provided to Pediatric Patients with Hemophiliaand Von Willebrand Disease at the Dental Clinic of the Hospital del Niño,Panama. | SOL LAIZ TORRES | ![]() |
![]() |
|||
80-Mo | Australia and New Zealand Inhibitors Workshop: Meeting the Challenges | Colleen McKay | ![]() |
![]() |
|||
81-Tu | Platelet procoagulant activity and thrombin generation in patients with severehemophilia | Amy Dunn | ![]() |
![]() |
|||
81-We | Through an ethical lens: ethics, pain management and family centered care | Liz Bishop | ![]() |
![]() |
|||
81-Mo | National educational programme in haemophilia in Ukraine | Galyna Moroz | ![]() |
![]() |
|||
82-Mo | Hemophilia patient outreach: Experience of Vietnam | Nguyen Thi Mai | ![]() |
![]() |
|||
82-We | Mothers of Children with Haemophilia: An Exploration of Their Experiences | Simon Brown | ![]() |
![]() |
|||
83-We | Understanding the challenges of distance and parenting a child with Haemophilia | Simon Brown | ![]() |
![]() |
|||
83-Mo | Twinning Programme between the Panamanian Foundation of Hemophilia and the CatalanAssociation of Hemophilia | Felipe Ortega | ![]() |
![]() |
|||
85-We | Guidelines for Growing: An action plan for parents of children with bleedingdisorders | Chad Feay | ![]() |
![]() |
|||
85-Tu | Concept Maps : an educational tool for teenagers with haemophilia ? | Céline Chenuel | ![]() |
![]() |
|||
85-Mo | MANAGEMENT OF PATIENTS WITH INHERITED BLEEDING DISORDERS IN THE EMERGENCYDEPARTMENT | Gianna Franca Rivolta | ![]() |
![]() |
|||
86-Mo | Challenges Faced to Develop Comprehensive Hemophilia Care in India & its Remedies | DEVILA SAHU | ![]() |
![]() |
|||
87-Mo | The HEMONLINE Project: preliminary results | Gianluca Sottilotta | ![]() |
![]() |
|||
89-We | Re-PEP Programme in New Zealand - an opportunity to review, re-visit, reflectand refresh. | Colleen McKay | ![]() |
![]() |
|||
89-Mo | Improved hemophilia care in developing countries through the World Federation ofHaemophilia twinning programmes: the case of Yaoundé and Geneva | Tayou Tagny Claude | ![]() |
![]() |
|||
89-Tu | Evaluation of the therapeutic education of 35patients with hemophilia | Amina Krim | ![]() |
![]() |
|||
90-Tu | Developing the design of a educational game for children with Hemophilia. | MARCIA APARECIDA PICCOLOTO MATTA | ![]() |
![]() |
|||
90-We | Family issues faced by women with bleeding disorders and importance ofpsychological help in overcoming them | Priyanka Rawat | ![]() |
![]() |
|||
91-We | FACTOR IX SECRETION IN HUMAN ADIPOSE-DERIVED STEM CELLS BY NON-VIRAL GENETRANSFER | ANTONIO LIRAS | ![]() |
![]() |
|||
91-Tu | OPTIMIZE THE HEMOPHILIA ATTENTION, IN THE EMERGENCY ROOM, THROUGH A EDUCATIONMANUAL TO PRIMARY PHYSICIANS AND NURSES IN PANAMA | MORENO BELGICA | ![]() |
![]() |
|||
92-Tu | Severe Bleeding Disorder Alert Cards | Brian OMahony | ![]() |
![]() |
|||
93-Tu | MULTIDISCIPLINARY FORMATION AND TREATMENT IN HEMOPHILIA. A MEXICAN PILOT PROJECTCONTRIBUTION FROM THE HEALTH PSYCHOLOGY | Maricela Osorio | ![]() |
![]() |
|||
93-We | The impact of home treatment in the management of hemophilia in developingcountries | El Khorassani Mohamed | ![]() |
![]() |
|||
93-Mo | INTRACEREBRAL HEMORRHAGES IN PATIENTS WITH HEMOPHILIA: THREE YEARS OF FOLLOW-UPAT THE COMPREHENSIVE CARE PROGRAM IN CUBA (2008-2010). | Dunia de la Caridad Castillo González | ![]() |
![]() |
|||
94-Tu | Dont Push Your LuckBoard Game for Childrens Decision Making in their Hemophilia Care | Lisa Semple | ![]() |
![]() |
|||
95-Tu | HEMOPHILIA: TEACHING PROGRAM AT THE UNIVERSITY OF VALENCIA (SPAIN) | QUEROL FUENTES FELIPE | ![]() |
![]() |
|||
95-Mo | Clinical outcome in a cohort of HIV/HCV coinfected patients. HCV RNA presenceassociated to higher GGT levels. | Aloisi Zavala Natalia | ![]() |
![]() |
|||
96-Mo | Distribution of IL28b gene polymorphisms and presence of 32bp CCR5 deletion in acohort of HIV/HCV coinfected patients. | Maria Cecilia Monzani | ![]() |
![]() |
|||
96-Tu | The Development of a Tool to Assist Patients in Identifying Health Care Coverage- Personal Health Insurance Toolkit | Michelle Rice | ![]() |
![]() |
|||
96-We | Home clinical assistance: ITALIAN SURVEY OF HCA SUPPORT FOR THE MANAGMENT OF CVCIN PEDIATRIC HEMOPHILIC PATIENTS IN PROPHYLAXIS. | Ezio Zanon | ![]() |
![]() |
|||
97-Tu | Pedagogical practices with the use of Informatics resources for people withHemophilia | Cristiane Santos | ![]() |
![]() |
|||
97-Mo | Evaluation of liver fibrosis in haemophilia patients with HCV infection usingtransient elastography - Fibrotest. | Angelika Batorova | ![]() |
![]() |
|||
98-We | Effect of in vivo induction of regulatory T cells forimmune toleristaion andeffect on FVIII inhibitor anamnestic response | Simon Brown | ![]() |
![]() |
|||
99-We | Factor VIII product-dependent recognition of anti-factor VIII antibodies | Saulius Butenas | ![]() |
![]() |
|||
100-We | HOW MANY PATIENTS WITH HIGH-RESPONDING INHIBITORS DO/DID NOT UNDERGO IMMUNETOLERANCE INDUCTION IN ITALY? WHY NOT? | Antonio Coppola | ![]() |
![]() |
|||
101-Tu | NEW Teaching strategy: educational MANUAL of Hemophilia and VON WILLEBRAND forparents and patients in PANAMA. | VILLALAZ LUZ | ![]() |
![]() |
|||
101-We | RISK OF BLEEDING AND INHIBITOR DEVELOPMENT AFTER CIRCUMCISION OF PREVIOUSLYUNTREATED(PUPs) OR MINIMALLY TREATED(MTPs) SEVERE HEMOPHILIA A PATIENTS | Mohsen Elalfy | ![]() |
![]() |
|||
102-Tu | Development of an educational tool for haemophiliacs : advices of the pharmacist | Anne-Sophie Leromain | ![]() |
![]() |
|||
102-We | Plasma-exchange and immunosuppressive therapy in a patient with mild hemophiliaA and inhibitors complicated by severe muscular bleeding and compartmentalsyndrome | Chiara Ambaglio | ![]() |
![]() |
|||
103-Mo | The development of Japanese blood program for assuring safety in supplying domestic coagulation blood products: A case study of the Japanese Red Cross Society | Masatake Hongo | ![]() |
![]() |
|||
104-We | Presence and evolution of anti-factor VIII (FVIII) catalytic activity in severe,mild or moderate hemophilia patients with FVIII inhibitors | Sandrine Grosbois | ![]() |
![]() |
|||
104-Tu | Education: effective tool in the prevention of complications and appropriatemanagement of Haemophilias patient in Panama. | FRNCO ANAYANSI | ![]() |
![]() |
|||
105-Tu | BENEFITS FROM WHF TWINNING AND TEACHING PROGRAMS,OUR EXPERIENCE. | GUADALUPE VIVERO | ![]() |
![]() |
|||
106-Mo | Like a curse: Outcomes of the New Zealand 2011 People with Haemophilia andHepatitis C Survey | Chantal Lauzon | ![]() |
![]() |
|||
106-Tu | Use of short message service (SMS) to document bleeding episodes in childrenwith haemophilia | Carolyn Broderick | ![]() |
![]() |
|||
107-Tu | BLOOD 4 : A blog to cope with Hemophilia with the use of images | Frederica R.M.Y cassis | ![]() |
![]() |
|||
108-Tu | Remote Control: Is it enough? | Desdemona Chong | ![]() |
![]() |
|||
111-Mo | Number of Patients with Coagulation Disorders in Japans 2010 Annual Report fromthe Research Committee for the National Surveillance on Coagulation Disordersin Japan | SHINOBU TATSUNAMI | ![]() |
![]() |
|||
111-Tu | Social Network for Girls and Women with Bleeding Disorders | Cheryl DAmbrosio | ![]() |
![]() |
|||
112-Mo | The running infection of hepatitis C virus (HCV) diagnosis is too late in femalewith Severe Hereditary Clotting Factor Disorders (SHCFD): French single Centreexperience. | peynet peynet | ![]() |
![]() |
|||
113-Mo | An attempt to analyze the narrative world of the life-stories of doctors andpatients involved in the HIV tainted blood product incident in Japan | Masatake Hongo | ![]() |
![]() |
|||
114-Mo | Decrease of microparticles (MP) after the treatment in hemophilia A patients:Coincidence or causation? | Jovan P Antovic | ![]() |
![]() |
|||
114-Tu | Role of Telemedicine in managing Bleeding disorders in rural Pakistan | Tahira Zafar | ![]() |
![]() |
|||
115-Mo | Characterizing Global Hemostasis Throughout the FVIII Prophylaxis DosingInterval: A Pilot Study | Donald Brophy | ![]() |
![]() |
|||
116-Mo | A CIRCULATING HEPARIN-LIKE ANTICOAGULANT WITH NO BLEEDING COMPLICATIONS: CASE REPORT | Desiree Coen Herak | ![]() |
![]() |
|||
117-Tu | Successful Orthotopic Liver Transplantation in a Patient with Severe HaemophiliaA and High Titre Factor VIII Inhibitor | Richard Gregg | ![]() |
![]() |
|||
118-Mo | Hemophilia A prenatal diagnosis by factor VIII clotting activity usingpercutaneous umbilical blood sampling | Yunhai Fang | ![]() |
![]() |
|||
119-Mo | Haemophilia - a missed diagnosis | Naresh Gupta | ![]() |
![]() |
|||
119-We | Successful Immune Suppression Followed by Immune Tolerance Induction in a Factor9 Patient Who had Developed an Anaphylactic Reaction to Factor 9. | Nancy Hodgson | ![]() |
![]() |
|||
119-Tu | Life itself. Different visions of hemophilia | Otilia Ragull | ![]() |
![]() |
|||
120-Mo | Investigation of a prolonged APTT: Date from a UK NEQAS for Blood Coagulationexercise | Ian Jennings | ![]() |
![]() |
|||
120-We | Plasma Exchange and Continuous Infusion of Factor VIII for Life-Saving Surgeryin Hemophilia A with High-Titer Inhibitor: Two Case Reports | Rungrote Natesirinilkul | ![]() |
![]() |
|||
120-Tu | Caring for Mild Hemophilia: A Challenge to Comprehensive Hemophilia TreatmentCenters | M Dawn Goodyear | ![]() |
![]() |
|||
121-We | Successful low-dose immune tolerance induction regimen using multiple plasma-derived factor VIII concentrates. | Marina Pereira Colella | ![]() |
![]() |
|||
121-Tu | Development and Evaluation of a Self-assessment Pathway for Young Men with Mild Hemophilia | JoAnn Nilson | ![]() |
![]() |
|||
122-Mo | NEW QUANTITATIVE aPTT WAVEFORM ANALYSIS ON BEHRING COAGULATION SYSTEM | Marija Milos | ![]() |
![]() |
|||
122-We | IgG4 subclass of anti-FVIII antibodies is correlated to high-titer inhibitor,whereas IgG1 subclass is related to low-titer inhibitor in hemophilia Apatients. | Margareth Ozelo | ![]() |
![]() |
|||
123-We | Genetic risk factors for inhibitor development in a Brazilian severe hemophiliaA population | Margareth Castro Ozelo | ![]() |
![]() |
|||
123-Mo | UTILITY OF NEW QUANTITATIVE aPTT WAVEFORM ANALYSIS IN LABORATORY MANAGEMENT OFHEMOPHILIA A PATIENTS | Marija Milos | ![]() |
![]() |
|||
124-Mo | Validating the Role of Thrombelastography and the Thrombin Generation Assay forRoutine Clinical Care in Children with Haemophilia | Manfred Rauh | ![]() |
![]() |
|||
124-We | Sequential therapy with activated prothrombin complex concentrate andrecombinant factor VIIa in the treatment of unresponsive bleeding in patientswith hemophilia and inhibitors in a single center experience | Young Shil Park | ![]() |
![]() |
|||
125-Tu | The Royal Family: A Project to Increase Awareness of Hemophilia in Slovakia | Jaroslav Janovec | ![]() |
![]() |
|||
125-Mo | Modified Inverse shifting-PCR (IS-PCR) to investigate Intron 22 Inversion | federica riccardi | ![]() |
![]() |
|||
126-Mo | Molecular Analysis of mild haemophilia patients: the experience of a singlecentre | federica riccardi | ![]() |
![]() |
|||
126-Tu | Cerebral hemorrhage in a Malagasy with haemophilia B | AIMEE OLIVAT RAKOTO ALSON | ![]() |
![]() |
|||
127-We | Resolution of Nephrotic Syndrome Following Rituximab Therapy in a PatientUndergoing Immune Tolerance Induction | Susan Kearney | ![]() |
![]() |
|||
128-Tu | Bile Acid deficiency as cause of VKCFD in a Newborn | Matthias Watzka | ![]() |
![]() |
|||
128-We | Impact of HLA and cytokines polymorphisms on inhibitors development in childrenwith severe Haemophilia A | Helen Pergantou | ![]() |
![]() |
|||
129-Tu | Benefits of an Individual Communication Strategy from a National Haemophilia Society | Anne Duffy | ![]() |
![]() |
|||
129-Mo | Evaluation of Hemostatic Effect of BAY 86-6150, a Recombinant FVIIa Variant, inAntibody-Induced Hemophilic Whole Blood Under Flow Conditions | Mitsuhiko Sugimoto | ![]() |
![]() |
|||
130-We | Experience of surgery in patients with haemophilia with inhibitors | Tatiana Polyanskaya | ![]() |
![]() |
|||
131-Mo | Stability of clotting factors in fresh frozen plasma in the University TeachingHospital of Yaoundé, Cameroon | Tayou Tagny Claude | ![]() |
![]() |
|||
132-Mo | Thromboelastography as screening test for the diagnosis of Scott Syndrome. | paula villaca | ![]() |
![]() |
|||
132-We | Identification of potential T-cell epitopes in factor VIII using peptidemicroarrays | Kathleen Pratt | ![]() |
![]() |
|||
133-We | A Canadian survey on the incidence and risk factors for inhibitor development insevere hemophilia A PUPs: 2005-2010. | Georges-Etienne Rivard | ![]() |
![]() |
|||
134-We | F8 genotype and not polymorphisms in IL10, TNFA and CTLA4 influences inhibitor development in Argentine patients with severe HA. | Liliana Rossetti | ![]() |
![]() |
|||
135-We | Circumcision experience in severe hemophilia patients with inhibitors | Sasmaz Ilgen | ![]() |
![]() |
|||
136-Mo | Heterozygote frequencies of common polymorphic markers of factor VIII (F8) and factor IX (F9) genes in indigenous Nepali population | Shrimati Shetty | ![]() |
![]() |
|||
137-We | Prospective ADVATE Immune Tolerance Induction Registry (PAIR) in Hemophilia APatients with Inhibitors: Interim Report | Gerald Spotts | ![]() |
![]() |
|||
138-We | ALLELE POLYMORPHISMS OF IMMUNE RESPONSE GENES IN SEVERE HAEMOPHILIA A PATIENTSWITH INHIBITORS IN UKRAINE | Oleksandra Stasyshyn | ![]() |
![]() |
|||
138-Mo | Various genetic mechanisms resulting in phenotypic expression of haemophilia A in three females | Virginie Barbay | ![]() |
![]() |
|||
139-We | Case series report - low-dose immune tolerance (ITI) in Iran | shirin Tehrani Tarighat | ![]() |
![]() |
|||
140-Mo | Duplications Xq28 and Hemophilia are questionable for genetic counselling | Catherine Costa | ![]() |
![]() |
|||
140-Tu | Differences in the Bleeding Phenotypes of Haemophilia A and B | Berthold Siegmund | ![]() |
![]() |
|||
141-Mo | Spectrum of mutations in 407 unrelated haemophilia B patients | Costa Catherine | ![]() |
![]() |
|||
143-Mo | A third rearrangement caused by homologous recombination between inverted repeats at Xq28 cause severe hemophilia A | Behnaz Pezeshkpoor | ![]() |
![]() |
|||
145-Mo | Inversion 22 in Hemophilia A in the North Indian Population: a New cDNA BasedProtocol | Praveen Kumar | ![]() |
![]() |
|||
145-We | Genotype-phenotype Correlation in Hemophilia A and Risk of Inhibitors of F8 genemutations | kiyoung yoo | ![]() |
![]() |
|||
145-Tu | The method of concentration of blood clotting factor VIII usingcross-galvanization in patients with hemophilia A | Kate Kabaeva | ![]() |
![]() |
|||
146-Tu | A New Clinical Tool to Measure Balance and Mobility in Hemophilia: the CommunityBalance and Mobility Scale. | Cecily Bos | ![]() |
![]() |
|||
149-Mo | INTRACELLULAR TRAFFICKING ANALYSIS OF C111Y AND C111S MUTATIONS IDENTIFIED INFACTOR IX FROM MEXICAN PATIENTS WITH SEVERE HEMOPHILIA B | JOHANNA MANTILLA CAPACHO | ![]() |
![]() |
|||
149-We | Prevalence of inhibitor antibodies in the Mazandaran(North of Iran) haemophiliaA population. | Hassan Mahmoodi Nesheli | ![]() |
![]() |
|||
150-Mo | GENETICS DEFECTS IN VON WILLEBRAND DISEASE. | Rosario Pérez Garrido | ![]() |
![]() |
|||
150-We | USE OF FACTOR VIII CONCENTRATES IN LIFE-THREATENING BLEEDING IN HEMOPHILICPATIENTS WITH INHIBITOR | Hugh C Kim | ![]() |
![]() |
|||
150-Tu | ADVATE HaEmophlia A Outome Database (AHEAD): A long-term registry focusing onjoint health outcomes and health-related quality of life | Gerald Spotts | ![]() |
![]() |
|||
151-Tu | A Post-Authorisation Safety Surveillance of ADVATE, Recombinant Antihemophilic Factor, Plasma/Albumin-Free Method (rAHF-PFM) in Hemophilia A | Jenny Chou | ![]() |
![]() |
|||
151-We | Intracranial Hemorrhage (ICH) in a 5-years-old Child with Severe Hemophilia Band Inhibitors with Anaphylaxis: Treatment Issues | Carvalho Manuela | ![]() |
![]() |
|||
151-Mo | Absence of active F8 protein despite high F8 mRNA expression levels in a severeHaemophilia A patient | Behnaz Pezeshkpoor | ![]() |
![]() |
|||
152-We | Prevalence of inhibitor in a prospective cohort of hemophilic children under 4years of age from a single center. | Florencia Tisi Baña | ![]() |
![]() |
|||
152-Mo | IDENTIFICATION OF MUTATIONS ASSOCIATED WITH HAEMOPHILIA A: A FRENCH CARIBBEANEXPERIENCE | Serge PIERRE-LOUIS | ![]() |
![]() |
|||
152-Tu | Estimated Annual Infusion Volume Reduction with a 2 mL Reconstitution Volume forADVATE | josh epstein | ![]() |
![]() |
|||
153-Mo | The Canadian National Program for Hemophilia Mutation Testing database: aten-year anniversary review. | Natalia Rydz | ![]() |
![]() |
|||
153-We | Successful use of negative pressure wound therapy in a patient with severeHemophilia A and an inhibitor | Vicky Hanneman | ![]() |
![]() |
|||
154-Tu | Pain in Haemophilia. Assessment of type of pain, coping styles and analgesicuse. | bj ramsay | ![]() |
![]() |
|||
155-We | RADIOACTIVE SYNOVECTOMY of the SHOULDER JOINT in PATIENTS with HAEMOPHILIA | Semih Aydogdu | ![]() |
![]() |
|||
155-Tu | Pain and Meaning: from the injury to the experience of pain | Ceres Lotito | ![]() |
![]() |
|||
156-Mo | Clinical implementation of Clinician-oriented locus specific mutation detectionand deposition system | kiyoung yoo | ![]() |
![]() |
|||
156-We | The management of domiciliary acute haemarthrosis by ultrasonography: experiencein a single center. | AZNAR LUCEA JOSE ANTONIO | ![]() |
![]() |
|||
157-We | Autologous stem cell treatment in hemophilic arthropathy. | Aymara Baganet Cobas | ![]() |
![]() |
|||
158-We | KNEE ON FLEXION: OSTEOTOMY OF FEMORAL EXTENTION IN PEDIATRIC PATIENTS WITH HAEMOPHILIA | ROBERTO BERNAL-LAGUNAS | ![]() |
![]() |
|||
159-Mo | Gene rearrangements and mutations in Malaysian patients with Haemophilia A | maimiza zahari | ![]() |
![]() |
|||
159-We | Abnormal inter-extremity difference (AIED) of quadriceps muscle strength and relationship to patellar tendon thickness and joint status in PWH | Alexander Brunner | ![]() |
![]() |
|||
159-Tu | Central Venous Line Insertion and Factor Replacement Therapy in Patients with Haemophilia A: a local experience. | Adriana Fonseca | ![]() |
![]() |
|||
160-Tu | Obesity management in boys with severe haemophilia: What works? | Nicola Hamilton | ![]() |
![]() |
|||
161-Mo | Role of nurse in improving hemophilia care | Fayal Bouaballou | ![]() |
![]() |
|||
162-Mo | Inherited Bleeding Disorders- The Nursing Experience of Patient and Family CareNeeds in the Paediatric Setting. | Gill Doyle | ![]() |
![]() |
|||
163-Tu | Constraints and challenges in treating a young haemophiliac with exceptionallyhigh inhibitor titers. | Andromachi Papagianni | ![]() |
![]() |
|||
163-Mo | The needs and support measures of Japanese haemophilic careers(JHC): discussionfrom literature review. | tomie fujii | ![]() |
![]() |
|||
165-We | Frequency , risk factors and consequences of Decreased Bone mineral Density inchildren with Hemophilia A and B | PEYMAN ESHGHI | ![]() |
![]() |
|||
165-Tu | A Survey of Current Canadian Practice in the Care of Newborn Boys withHemophilia | Paul Moorehead | ![]() |
![]() |
|||
165-Mo | Evaluation of methods of identifying carriers of haemophilia. | Anne Gillham | ![]() |
![]() |
|||
166-We | Pseudotumours in mild haemophiliacs - a rare pathology. | joanna farrant | ![]() |
![]() |
|||
168-Mo | Optimising health outcomes for childrenliving with Haemophilia in rural communitiesby forging partnerships betweenHaemophilia Treatment Teams and Local Health Networks | Anne Jackson | ![]() |
![]() |
|||
169-We | Total Knee Replacement in patients with Hemophilia - a follow-up of 30 patients | Bjoern Habermann | ![]() |
![]() |
|||
170-We | Autologous Chondrocyte Implantation in a patient with severe Hemophilia | Bjoern Habermann | ![]() |
![]() |
|||
172-Mo | Using motivational interviewing techniques to enhance therapeutic relationshipswith adult and pediatric hemophilia clients | Lois Logie | ![]() |
![]() |
|||
172-We | Iliopsoas haemorrhage in patients with haemophilia. | Denisa Jankovic | ![]() |
![]() |
|||
173-Mo | A Successful Model of a Nursing Short Message System (SMS) for ImprovingHemophilia Care in South China | Jing SUN | ![]() |
![]() |
|||
173-Tu | Preclinical safety pharmacology of a PEGylated variant of recombinant factor VIII | Eva Muchitsch | ![]() |
![]() |
|||
174-Tu | Pharmacokinetics of a Recombinant Factor VIIa in Factor VIII ko Mice, Rats andMacaques | Eva-Maria Muchitsch | ![]() |
![]() |
|||
174-We | ETPS - AN EFFECTIVE MODALITY IN CHRONIC SYNOVITIS TO ENHANCE ACTIVITY | Dr. Jayashri Kale | ![]() |
![]() |
|||
175-Tu | Single Dose Pharmacokinetics of a PEGylated Variant of Recombinant FVIII inFactor VIII ko Mice, Rats and Macaques | Eva-Maria Muchitsch | ![]() |
![]() |
|||
175-We | Factor IX (FIX) deficiency and a swollen knee: not always a bleed | Susan Karp | ![]() |
![]() |
|||
176-Tu | Single Dose Pharmacokinetics of Recombinant FIX in Factor IX ko Mice, Rats andMacaques | Eva-Maria Muchitsch | ![]() |
![]() |
|||
176-Mo | Networking in Hemophilia and other Bleeding Disorders Care:The Canada-Germany Nurse Experience | Nancy Hodgson | ![]() |
![]() |
|||
177-Tu | Preclinical safety pharmacology of a new recombinant factor IX | Eva Muchitsch | ![]() |
![]() |
|||
178-Mo | Self-modification of Regimens by Hemophilia Patients in Japan | Kayoko Omura | ![]() |
![]() |
|||
178-Tu | Evolution of management of pregnancies at-risk for haemophilia in France in the last ten years: Impact of non-invasive foetal sex determination | Catherine Costa | ![]() |
![]() |
|||
179-We | Radiosynovectomy in Chronic Recurrent Haemophilic Haemarthrosis: The NorthEastExperience. | Munir Khan | ![]() |
![]() |
|||
180-We | Results of ankle prosthesis in patients with severe haemophilic arthropathy -follow up | Manuela Krause | ![]() |
![]() |
|||
180-Mo | EXPERIENCE IN VENOUS CENTRAL CATHETER (PORT-A-CATH) IN PEDIATRICS, FORTREATMENT OF HEMOPHILIA AND VON WILLEBRAND DISEASE IN PANAMA. | VILLALAZ LUZ | ![]() |
![]() |
|||
181-Mo | Experience of the use of Veinviewer for DIVA patients with hemophilia | kiyoung yoo | ![]() |
![]() |
|||
182-Mo | Case report of Heart surgery of the patient with bleeding disorder | roxana kabiri movahhed | ![]() |
![]() |
|||
182-We | Joint Preservation Post Ankle Arthrodesis in Hemophilia: A Review | Heidi Lane | ![]() |
![]() |
|||
182-Tu | Observational study for improving adherence with prophylaxis in haemophilia | KAGEHIRO AMANO | ![]() |
![]() |
|||
183-We | Outcomes in Activity, Participation and Body Structure Following AnkleArthrodesis in Persons with Hemophilia: Analyses Using the Universal DataCollection Surveillance Project | Heidi Lane | ![]() |
![]() |
|||
183-Mo | QUALITY OF LIFE FOR PATIENTS WITH HEMOPHILIA | Glbahar Keskin | ![]() |
![]() |
|||
184-We | Intra-Articular Hyaluronic Acid in Treating of Haemophilic Knee Arthropathy | Tsung-Ying Li | ![]() |
![]() |
|||
184-Tu | SECONDARY PROPHYLAXIS IN ADULT SEVERE HAEMOPHILIC PATIENTS: A PROSPECTIVE STUDYIN A SINGLE CENTER. | JOSÉ ANTONIO AZNAR | ![]() |
![]() |
|||
185-Mo | Study of adherence to prophylactic treatment in severe A haemophilic patients | JOSÉ ANTONIO AZNAR | ![]() |
![]() |
|||
185-Tu | Pharmacokinetic-Pharmacodynamic (PK/PD) Modeling of Factor VIII (FVIII) Usingits Plasma Concentration and Global Hemostasis Biomarkers: | Donald Brophy | ![]() |
![]() |
|||
185-We | Haemophilic Arthropathy and Health-Related Quality of Life in Haemophilic Patients in Taiwan | Tsung-Ying Li | ![]() |
![]() |
|||
186-Tu | COMPARISON TWO LABORATORY ASSAYS IN MONITORING EFFICACY OF DIFFERENTPROPHILAXIS REGIMENS FOR SEVERE HAEMOPHILIA | Irena Djunic | ![]() |
![]() |
|||
187-Tu | Successful Secondary Prophylaxis in Haemophilia with Inhibitors using rFVIIaThree Times per Week | Monica Martinez | ![]() |
![]() |
|||
188-Tu | Bleeding Patterns In Severe Hemophilia A Infants and Toddlers On Prophylaxis VsOn Demand Therapy:A Prospective Randomized Observational Study | Mohsen Elalfy | ![]() |
![]() |
|||
188-We | SUBPERIOSTEAL/INTRAMUSCULAR PSEUDOTUMOUR- SURGICAL TREATMENT BY INTRALESIONALCURRETTAGE OR WIDE EXCISION | SHUBHRANSHU MOHANTY | ![]() |
![]() |
|||
189-We | Hemarthrosis results in an increase in Synovial Fibrinolytic activity in Hemophilia Mice | laurens nieuwenhuizen | ![]() |
![]() |
|||
189-Mo | Multicenter study of pediatric quality of life and psychomotor development inparents of children with severe and moderate hemophilia who receive primaryprophylaxis treatment in public hospitals in Chile | Claudia Bularte | ![]() |
![]() |
|||
190-We | Identification - and differences in expression - of the iron regulatorsFerroportin, Hepcidin, Hemoglobin Scavenger Receptor CD163, Heme Carrier Protein1, and Heme Exporter FLVCR in Healthy, Osteoarthritic, Rheumatoid, andHemophilic Synovium. | Laurens Nieuwenhuizen | ![]() |
![]() |
|||
190-Mo | The Impact of Pediatric Psychology on Identification of Psychosocial Needs | Cathliyn Buranahirun | ![]() |
![]() |
|||
191-Mo | Pedagogical attention programme. Results after 18 year s experience. | Patricia Cabré | ![]() |
![]() |
|||
192-Tu | Adherence to Prophylaxis Treatment Regimens among Persons with Severe Hemophilia A and B: Results from a 1-Year, Single Institution Study | Miguel Escobar | ![]() |
![]() |
|||
192-Mo | Social Participation in Boys with Hemophilia | Aubrey Chiu | ![]() |
![]() |
|||
193-We | Prospective Evaluation of Safety and Efficacy of Radioactive Synovectomy with90Yttrium-Hidroxyapatite and 153Samarium-Hidroxyapatite in Chronic HemophilicSynovitis | JANAINA BOSSO J SILVA | ![]() |
![]() |
|||
193-Tu | Prophylaxis with increasing doses, our experience about 8 cases | FAIZA MEZHOUD | ![]() |
![]() |
|||
194-We | Conservative Treatment of Severe Knee Flexion Contracture in Two Patients withSevere Hemophilia A Patients with High-responding Inhibitors | Margareth Ozelo | ![]() |
![]() |
|||
195-We | Surgical treatment of the hemophilic pseudotumor:a single center experience | Joannis Panotopoulos | ![]() |
![]() |
|||
195-Mo | Childhood and subjective timings: growing up with hemophilia | Silvia Grases | ![]() |
![]() |
|||
196-Mo | Psycho-social issues in haemophilia- 100 case studies | Naresh Gupta | ![]() |
![]() |
|||
196-Tu | SECONDARY PROPHYLAXIS IN HEMOPHILIAC ADULTS WITH ARTHROPATHY. DESCRIPTION OF ACOHORT. | Carlos Ramírez | ![]() |
![]() |
|||
197-Tu | SECONDARY PROPHYLAXIS WITH ANTI INHIBITOR COAGULANT COMPLEX (AICC): FROMANECDOTE TO REALITY | Maria Helena Solano | ![]() |
![]() |
|||
197-Mo | :Psychosocial Issues-support for People With Hemophilia & their families inIndia: | Meera Suresh Hanagavadi | ![]() |
![]() |
|||
198-Tu | Tailored primary prophylaxis with dose-escalation in Iranian haemophilia A | shirin Tehrani Tarighat | ![]() |
![]() |
|||
198-Mo | THE PSYCHOLOGY WORK AT CENTRO DOS HEMOFLICOS DO ESTADO DE SO PAULO - CHESP | Reiko Hanashiro | ![]() |
![]() |
|||
199-We | ULTRASONOGRAPHY PROTOCOL FOR DIAGNOSIS AND CONTROL OF ACUTE HEMARTHROSIS INHAEMOPHILIC PATIENTS | QUEROL FUENTES FELIPE | ![]() |
![]() |
|||
200-We | Does prophylaxis have an effect on bone strength beyond physical activity? | Anne Mkipernaa | ![]() |
![]() |
|||
201-Tu | Long-term low-dose secondary prophylaxis for severe and moderate hemophiliachildren with arthropathy: A single-center prospective study in China | Ada Xu | ![]() |
![]() |
|||
202-Tu | Hemophilic arthropathy in pediatric patients with hemophilia A: comparison ofearly and late prophylaxis. | kiyoung yoo | ![]() |
![]() |
|||
202-Mo | Restructuring and improving QOL in Japanese HIV victims with hemophilia andtheir families: How do we rebuild our life with effective support? | Akiko Kakinuma | ![]() |
![]() |
|||
203-We | Bone mineral density in hemophiliac patients | Nader Roushan | ![]() |
![]() |
|||
204-Tu | Prophylaxis vs. On Demand Treatment in Adults with Severe Hemophilia A. | Cecily Bos | ![]() |
![]() |
|||
206-Mo | Mind Inhibitors | Walid Kobisi | ![]() |
![]() |
|||
206-Tu | What do Canadian men living with Hemophilia need to know to facilitate optimaldisease management? A mixed methods approach | Shannon Lane | ![]() |
![]() |
|||
207-Tu | The Effect of yoga technique on quality of life in children and adolescentswith haemophilia referring to Dastgheib hospital .1389 Shiraz University OfMedical Siences SHIRAZ-IRAN | Noushin Beheshtipoor | ![]() |
![]() |
|||
208-We | Long-term studies of hemophilic arthropathy by Petterssons score - Evidencesthat joint damages in hemophiliacs occur predominantly in early years of life | Ming-Ching Shen | ![]() |
![]() |
|||
208-Mo | A NEW TOOL TO ASSESS COPING AND PERCEPTION OF CHILDREN WITH HAEMOPHILIA | Perrine Limperg | ![]() |
![]() |
|||
209-Mo | HEALTH RELATED QUALITY OF LIFE OF BOYS WITH HAEMOPHILIA AND PARENTS ILLNESS PERCEPTIONS | Perrine Limperg | ![]() |
![]() |
|||
210-We | Age-related changes of joint status in adults with severe haemophilia in Germany | Franziska Staeuber | ![]() |
![]() |
|||
211-Mo | Social support and economic stability as major determinants of self-esteem amongpersons with hemophilia | Marko Marinic | ![]() |
![]() |
|||
211-Tu | Quality of life of hemophilic children on prophylactic or on demand treatmentregimens in Iran | PEYMAN ESHGHI | ![]() |
![]() |
|||
212-Tu | The Place of the Pictorial Blood Assessment Chart in the appreciation of qualityof life in women with inherited bleeding disorders. | Anis Fadhlaoui | ![]() |
![]() |
|||
212-We | Osteochondral lesions of the ankle joint in patients with hemophilia A. A retrospective case series. | Karen Strike | ![]() |
![]() |
|||
213-Tu | Quality of life during menstruations in women with inherited bleeding disorders(About 31 patients) | Anis Fadhlaoui | ![]() |
![]() |
|||
213-Mo | A 10-year follow up of an HIV/HCV co-infected hemophilia A after living donorliver transplantation | Eiichi Mizukoshi | ![]() |
![]() |
|||
214-Mo | At a loss as to where to go from here? | Daryl Pollock | ![]() |
![]() |
|||
215-We | Arthroscopic synovectomy with joint distraction using a patella tendon bearingbrace for severe hemophilic ankle arthropathy | YASUHITO TANAKA | ![]() |
![]() |
|||
215-Mo | Oral Mucosal Bleeding: A Nurses View | bj ramsay | ![]() |
![]() |
|||
216-Tu | FACTORS RELATED TO QUALITY OF LIFE IN HEMOPHILIA PATIENTS. | Miwa Goto | ![]() |
![]() |
|||
216-We | Radiosynovectomy with Yttrium and Samarium. 488 patients/842 injections. Preliminary report on radiation safety | Sylvia Thomas | ![]() |
![]() |
|||
216-Mo | Youth With Hemophilia In Pakistan | Sheikh Moin Riaz | ![]() |
![]() |
|||
217-Tu | Health Related Quality of Life Among Hemophilia Patients in North East Region ofIndonesia | Stefanus Gunawan | ![]() |
![]() |
|||
217-We | Blood coagulation aggravates joint damage after an experimental hemorrhage in acanine knee | Monique van Meegeren | ![]() |
![]() |
|||
218-We | Four-day continuous blood exposure leads to prolonged joint damage in a caninein vivo model, whereas intermittent blood exposure does not | Monique van Meegeren | ![]() |
![]() |
|||
219-Mo | Psychosocial Issues and support for PWH & their families in India | Meera Suresh Hanagavadi | ![]() |
![]() |
|||
220-Mo | COMPARATIVE STUDY OF FUNCTIONING FAMILY IN PATIENTS WITH HEMOPHILIA AND OTHERFAMILIES WITH DISEASE | Ana Torres-Ortuño | ![]() |
![]() |
|||
221-Mo | SCHOOLS OF FAMILIES FOR PARENTS OF CHILDREN WITH HEMOPHILIA | Ana Torres | ![]() |
![]() |
|||
223-We | Experimental evaluation of cartilage damage by hematic synovitis in rabbits byNuclear Magnetic Resonance control | Ana Laura Douglas Price | ![]() |
![]() |
|||
223-Mo | The Psychologic and Disease burden assessment in hemophilia children witharthropathy: a single-center study in China | Ada Xu | ![]() |
![]() |
|||
223-Tu | PATIENT REPORTED OUTCOMES IN CLINICAL HAEMOPHILIA PRACTICE | Perrine Limperg | ![]() |
![]() |
|||
224-We | PRELIMINARY RESULTS OF A PHYSIOTHERAPY PROTOCOL IN THE SECONDARY PROPHYLAXIS OFADULTS WITH HAEMOPHILA | QUEROL FUENTES FELIPE | ![]() |
![]() |
|||
224-Tu | Income and Anxiousness of Working Hemophiliacs in Japan | Takeshi Matsumoto | ![]() |
![]() |
|||
225-Tu | Treatment outcome in young adults survey of 8 Countries - Preliminary Results | Brian OMahony | ![]() |
![]() |
|||
226-Mo | Auto care for childrens | YURI ANDREA ARANGO BERNAL | ![]() |
![]() |
|||
227-Tu | HEALTH RELATED QUALITY OF LIFE (HrQoL) IN BLEEDING PROPHYLAXIS WITH AN ACTIVATEDPROTHROMBIN COMPLEX CONCENTRATE (APCC): RESULTS FROM THE PRO-FEIBA STUDY | silvia riva | ![]() |
![]() |
|||
227-Mo | ECONOMIC AND PSYCHO-SOCIAL CARE FOR HAEMOPHILIA PATIENTS IN MARTINIQUE, A FRENCHCARIBBEAN EXPERIENCE | Serge PIERRE-LOUIS | ![]() |
![]() |
|||
228-Tu | Linking Quality of Life Measures with the ICF/ICF-CY in Young People withHaemophilia | silvia riva | ![]() |
![]() |
|||
228-Mo | Screening of the Von Willebrand disease in the west Algeria. | BENLALDJ DRISS | ![]() |
![]() |
|||
229-We | A baseline assessment of physical disabilities in 372 haemophilia patients inNorthern India | Naresh Gupta | ![]() |
![]() |
|||
229-Tu | Difficulties faced by haemophilic students in Japan | Yukiko Seki | ![]() |
![]() |
|||
230-Tu | Description of a Canadian Cohort of Youth and Young Men with Hemophilia Based onHealth-Related Quality of Life Measures. | Jean St-Louis | ![]() |
![]() |
|||
230-We | Hemophilia at Physical Medicine and Rehabilitation, assessment of physical,functional and psychological aspects: Prospective study conducted at Oran hospital - Algeria | khaled layadi | ![]() |
![]() |
|||
231-Mo | SINGLE CENTRE EXPERIENCE OF THE GP1B LATEX IMMUNOASSAY AND RISTOCETIN COFACTOR ASSAY - A COMPARATIVE STUDY. | David Davies | ![]() |
![]() |
|||
231-Tu | Impact of Life Events and Transitions on Health-Related Quality of LifeMeasurements in Youth and Young Adults with Hemophilia. | Jean St-Louis | ![]() |
![]() |
|||
232-Tu | Quantitative word mapping of hemophiliac patients opinions based on free-answerdescriptions on a quality-of-life questionnaire | SHINOBU TATSUNAMI | ![]() |
![]() |
|||
232-We | Assessment of Functional Independence Score In Hemophilia in Indian Children with Hemophilia | Sandeep H S | ![]() |
![]() |
|||
233-Mo | PARAPROTEIN SPECIFIC BINDING FOR PLATELET RECEPTOR GLYCOPROTEIN Ib AS A CAUSE OFACQUIRED VON WILLEBRAND SYNDROME IN MONOCLONAL GAMMOPATHIES | Irena Djunic | ![]() |
![]() |
|||
234-Tu | Understanding the Impact of Hemophilia on the Family: A Pilot Study of thePedsQL-Family Impact Module | Vicky Breakey | ![]() |
![]() |
|||
234-Mo | Expression Studies of von Willebrand Factor Missense Mutations Causing Type 1 orType 2 VWD | Hamideh Yadegari | ![]() |
![]() |
|||
235-Tu | Has the quality of life improved for children with haemophilia A? | Vaughan Williams | ![]() |
![]() |
|||
236-We | Strength training and stretching muscles of lower limbs in patients withhemophilia and arthropathy of the ankle. A pilot study. | RUBÉN CUESTA-BARRIUSO | ![]() |
![]() |
|||
236-Tu | HAEMO-QOL QUESTIONNAIRE FOR ADOLESCENTS: ASSESSING THE ITEM BLEEDING | Claudia Lorenzato | ![]() |
![]() |
|||
237-Tu | QUALITY OF LIFE IN RELATION TO SOCIAL AND EMOTIONAL SELF CONCEPT AND LIFE SATISFACTION | Luis Vañó Gisbert | ![]() |
![]() |
|||
237-We | Efficacy and safety of traction articular ankle arthropathy. A pilot study | RUBEN CUESTA-BARRIUSO | ![]() |
![]() |
|||
238-We | Clinical improvement of chronic arthropathy of the knee with manual therapy. Apilot study. | RUBÉN CUESTA-BARRIUSO | ![]() |
![]() |
|||
238-Tu | Swimming as a strategy to promote rehabilitation, physical fitness, mentalhealth and social inclusion to people and families suffering of Hemophilia andVon Willebrand. | YURI ANDRES ARANGO BERNAL | ![]() |
![]() |
|||
238-Mo | A pregnant woman with von Willebrand disease (VWD) type 2B: laboratory findingsand peripartal bleeding management | Katharina Holstein | ![]() |
![]() |
|||
239-We | In-hospital rehabilitation after multiple joint procedures (MJP) of the lowerextremities in persons with hemophilia (PWH) | Piet Kleijn, de | ![]() |
![]() |
|||
239-Tu | Psychometric properties of the Quality of Life Questionnaire in PediatricPatients with Hemophilia Mexico (QoLHMEX) | Maricela Osorio | ![]() |
![]() |
|||
240-Tu | Online Anthology of Individual Experiences by Girls and Women with BleedingDisorders | Cheryl DAmbrosio | ![]() |
![]() |
|||
240-Mo | Clinical diagnosis and laboratory screening in vWD pediatric patients of theNorthwestern of Mexico | Ana Rebeca Jaloma-Cruz | ![]() |
![]() |
|||
240-We | The Use of a Carbon-fiber Ankle Foot Orthosis and Therapeutic Exercise forManaging Pain in An Adolescent with Severe Blood-induced Ankle Joint ArthropathySecondary to Type 3 von Willebrand Disease | Sharon Funk | ![]() |
![]() |
|||
241-We | Recovery of the gait ability after total knee arthroplasty | Minoru Kubota | ![]() |
![]() |
|||
242-Mo | On demand therapy after ITT failure in a patient with von Willebrand diseasetype 3 and alloantibodies | Manuela Krause | ![]() |
![]() |
|||
243-We | Use of the Exergaming (Nintendo Wii) in the Rehabilitation of Patients withHemophilia. | JANAINA BOSSO JOSÉ DA SILVA | ![]() |
![]() |
|||
243-Tu | Prophylactic treatment in factor XI deficiency patients undergoing invasiveprocedures. | Philippe BEURRIER | ![]() |
![]() |
|||
244-We | Postural control in children with hemophilia. | Fabio Souza | ![]() |
![]() |
|||
245-We | Successful treatment outcome for an eight year old hemophilia boy withChronic Regional Pain Syndrome (CRPS) | Rachel Tiktinsky | ![]() |
![]() |
|||
245-Tu | Rare Inherited Bleeding Disorders: from a single centre in Pakistan. | MUNIRA BORHANY | ![]() |
![]() |
|||
246-Tu | Mutations causing severe Factor XIII deficiency in Pakistan | MUNIRA BORHANY | ![]() |
![]() |
|||
247-Mo | Prevalence of von Willebrand disease in Koreans | Sangkyu Park | ![]() |
![]() |
|||
247-We | The effect of 8-week aquatic exercise on Strength, Balance and Gait speed inhemophilia | kiyoung yoo | ![]() |
![]() |
|||
248-We | Improvement of walking ability of three inhibitors by rehabilitation | shimokawa akikko | ![]() |
![]() |
|||
249-Mo | Changes in von Willebrand factor level and von Willebrand activity with age in type 1 von Willebrand disease. | Natalia Rydz | ![]() |
![]() |
|||
250-Tu | The Canadian Experience: Severe Factor V Deficiency | M Dawn Goodyear | ![]() |
![]() |
|||
251-We | Serial casting on deformity with excercises is more effective than conventionalphysiotherapy treatment in people with hemophilia | Geeta Suri | ![]() |
![]() |
|||
252-We | THE OXIDATIVE STRESS AND ANTIOXIDANT STATUS AT CHILDREN WITH IMMUNETHROMBOCYTOPENIC PURPURA: ENDOTHELIAL NITRIC OXIDE SYNTHASE Glu298Asp GENEPOLYMORPHISM | Saadet Akarsu | ![]() |
![]() |
|||
253-Mo | Molecular Pathology of severe von Willebrand disease in Indian population | Shrimati Shetty | ![]() |
![]() |
|||
253-We | NORMAL PLATELET PARAMETERS IN CHILDHOOD PERIOD FROM NEWBORNS TO ADOLESCENTS | Saadet Akarsu | ![]() |
![]() |
|||
253-Tu | Laboratory Diagnosis of FXIII deficiency: Data from a UK NEQAS (BloodCoagulation) exercise | Ian Jennings | ![]() |
![]() |
|||
254-Mo | Polymorphic markers in VWF gene: Application in genetic diagnosis of affectedfamilies with VWD | Shrimati Shetty | ![]() |
![]() |
|||
255-We | Hemarthrosis an Unusual Presentation of Glanzmanns thrombasthenia | Bijan Keikhaei | ![]() |
![]() |
|||
256-Tu | Inherited Factor VII deficiency - perioperative replacement therapy is notnecessary in most cases | Robert Klamroth | ![]() |
![]() |
|||
256-Mo | Development of an automated VWF:RCo assay for measuring plasma samples with lowactivity | Peter L. Turecek | ![]() |
![]() |
|||
257-Mo | Analysis of the French cohort of 65 patients with type 2N von Willebrand diseaseidentifies distinct molecular/clinical entities. | Agnès VEYRADIER | ![]() |
![]() |
|||
258-Mo | French cohort of 37 patients with type 3 von Willebrand disease: molecular andclinical features | Agnès VEYRADIER | ![]() |
![]() |
|||
258-We | Identification of 5 new mutations in 9 Glanzmann Thrombasthenia patients | Ann-Kathrin Pilgrimm-Thorp | ![]() |
![]() |
|||
259-Tu | Factor XIII deficiency in Sistan and Baluchestan of Iran | Majid Naderu | ![]() |
![]() |
|||
260-Tu | Frequency & clinical spectrum of rare bleeding disorder in Pakistan,A multi centre study | Arshi Naz | ![]() |
![]() |
|||
260-We | Neurosurgery in a patient with Bernard-Soulier Syndrome | Elianna Saidenberg | ![]() |
![]() |
|||
261-Mo | Persistent acquired von Willebrand disease cases despite underlying neoplasmaremission. | Maria Eva Mingot Castellano | ![]() |
![]() |
|||
261-Tu | PROPHYLACTIC TREATMENT WITH ACTIVATED PROTHROMBIN COMPLEX CONCENTRATE IN APATIENT WITH SEVERE FACTOR X - FX- DEFICIENCY. | Jorge Peña Siado | ![]() |
![]() |
|||
262-We | 5 years Treatment report of hospitalized children with Glanzmannsthrombasthenia in a comprehensive hemophilia care center (2006-2011) | PEYMAN ESHGHI | ![]() |
![]() |
|||
262-Tu | Phenotypic classification of the mutations in coagulation factor IX segregate to different locations in its protein structure | Pavithra Meena Rallapalli | ![]() |
![]() |
|||
262-Mo | Thrombosis in patients with von Willebrands disease | Mirjana Mitrovic | ![]() |
![]() |
|||
263-Mo | Pregnancy outcomes in women with, and carriers of, inherited bleeding disordersin a London obstetric unit with Haemophilia Comprehensive Care Centre. | Imelda Balchin | ![]() |
![]() |
|||
264-Tu | Genotype-Phenotype correlation in families with mild factor VII deficiency | federica riccardi | ![]() |
![]() |
|||
265-Mo | CODEROUGE 2012 - 1st CANADIAN CONFERENCE ON BLEEDING DISORDERS IN WOMEN | Clare Cecchini | ![]() |
![]() |
|||
265-We | Physical and psychosocial benefits of exercise for patients with haemophilia | Lisa Blain | ![]() |
![]() |
|||
266-We | Haemophilia & Exercise Project (HEP): Subjective and objective physical performance in adult haemophilia patients after one year sports therapy programme | Doerte Czepa | ![]() |
![]() |
|||
268-Tu | THROMBOSIS OF THE ABDOMINAL AORTA IN CONGENITAL AFIBRINOGENEMIA. | Maria Teresa sartori | ![]() |
![]() |
|||
268-We | Development of a bleeds risk calculator | Rob Herbert | ![]() |
![]() |
|||
269-Mo | Current Postpartum Treatment Strategies for Von Willebrand Disease May NotAdequately Replace von Willebrand Factor | Andra James | ![]() |
![]() |
|||
269-Tu | Efficacy of a Recombinant ADAMTS13 in a Mouse Model of ThromboticThrombocytopenic Purpura | Eva-Maria Muchitsch | ![]() |
![]() |
|||
270-Mo | Pregnancy outcome of women with congenital bleeding disorders managed bymultidisciplinary team in a UK Haemophilia Comprehensive care centre over 3-yearperiod | DEEPA ARACHILLAGE | ![]() |
![]() |
|||
270-Tu | Delayed vitamin k deficiency related bleeding : is it genetically linked ? | Shrimati Shetty | ![]() |
![]() |
|||
270-We | Patterns of physical activity in Australian children with haemophilia. | Jane Latimer | ![]() |
![]() |
|||
271-Tu | Intracranial hemorrhage in an infant with severe Factor V deficiency | Jayson Stoffman | ![]() |
![]() |
|||
271-We | Quantifying the challenge: Proposal for evaluation of musculoskeletal system inswimmers with hemophilia undergoing intensive training. | MARIA MATILDE ROSAS CHACON | ![]() |
![]() |
|||
272-Tu | Factor XI deficiency: importance of von Willebrand factor level on haemorrhagicphenotype. | Fabienne VOLOT | ![]() |
![]() |
|||
272-We | Importance of Youth Groups in an National Member Organization | MUKESH GARODIA | ![]() |
![]() |
|||
274-Mo | Haemostatic Variations in Normal Women: The Role of Electronic Bleeding Questionnaire, Electronic Pictorial Chart and a Global Haemostatic Assay in Predicting Mild Bleeding Disorders in Women | Kimberly MacEachern | ![]() |
![]() |
|||
274-We | Understanding health and treatment decision making among youth with hemophilia:a qualitative approach | Shannon Lane | ![]() |
![]() |
|||
275-We | Participation of Children in National Haemophilia Conferences | Brian OMahony | ![]() |
![]() |
|||
275-Mo | Hematological and Gynecological Assesment in Haemophilia Carriers | Carlos Ramírez | ![]() |
![]() |
|||
276-Mo | Successful IVF and pregnancy in Glanzmanns thrombasthenia under cover of recombinant factor VIIa | Peter Staritz | ![]() |
![]() |
|||
276-Tu | Molecular analysis of congenital factor XI deficiency by High-Resolution Melting | federica riccardi | ![]() |
![]() |
|||
277-Mo | A Strategy for Women with Bleeding Disorders The Irish Experience | Debbie Greene | ![]() |
![]() |
|||
277-We | A Feasibility Study of Managing Hemophilia Online, An Internet-basedself-management and transitional care program for teens. | Vicky Breakey | ![]() |
![]() |
|||
278-Tu | Are They Really Rare?Prevalence of Rare Bleeding Disorders (RBDs) in North East of Iran | Zahra Badiei | ![]() |
![]() |
|||
279-We | Patients attitude to dental care | Andrew Brewer | ![]() |
![]() |
|||
296-LB | Evaluation of a 4-year External Quality Assessment Program on the Laboratory Diagnosis of Hemophilia in Brazil | Silmara Aparecida Lima | ![]() |
![]() |
![]() |
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. ![]() To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress. ![]() |
![]() |
||
![]() |